The invention relates to a novel cefazolin sodium compound and belongs to the technical field of medicine. According to the novel cefazolin sodium compound, in an X-ray powder diffraction spectrum obtained through Cu-Ka radionetric measurement, characteristic peaks are displayed at the positions where 2theta equals to 18.53 +/-0.1 degrees, 22.32 +/-0.1 degrees, 23.47 +/-0.1 degrees, 24.22 +/-0.1 degrees, 24.81 +/-0.1 degrees and 30.03 +/- 0.1 degrees, and an endothermic peak exists at the position where the temperature is 385-425 K in a differential scanning calorimetry spectrum. The novel cefazolin sodium compound is good in mobility, more meets requirements of technology of pharmaceutics and is more suitable for preparing various pharmaceutic preparations. Due to the fact that powder-injection prepared from the novel cefazolin sodium compound is good in stability, besides, solubility is good after the powder-injection is prepared into an injection solution, stability can reach 72 hours or above, storage time is greatly prolonged, therefore safety and efficiency of drug use are improved, and the occurrence rate of adverse reactions is avoided.